AbbVie has agreed to collaborate with Mission Therapeutics to develop deubiquitylating enzymes (DUBs) for the potential treatment of Alzheimer's disease and Parkinson's disease.
DUBs play a key role in maintaining cellular health by regulating the degradation of misfolded toxic proteins which are believed to cause impaired function and death of nerve cells in the brain. AbbVie and the Cambridge, England-based drug discovery and development company, Mission, are aiming to develop potential therapeutics that enable the degradation of toxic proteins and prevent their accumulation.
Under the terms of the agreement, both parties will collaborate during the research stage to identify specific DUBs and discover suitable compounds. AbbVie will then have the option to gain exclusive rights to develop and commercialize DUB inhibitors against up to four selected targets.
Read the press release